Literatur
Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA et al (2016) Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. Cancer 122(10):1523–1532
Monnier Y, Simon C (2015) Surgery versus radiotherapy for early oropharyngeal tumors: a never-ending debate. Curr Treat Options Oncol 16(9):42
Yeh DH, Tam S, Fung K, MacNeil SD, Yoo J, Winquist E et al (2015) Transoral robotic surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma—a systematic review of the literature. Eur J Surg Oncol 41(12):1603–1614
Holsinger FC, Ferris RL (2015) Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol 33(29):3285–3292
Melamed A, Rauh-Hain JA, Ramirez PT (2019) Minimally invasive radical hysterectomy for cervical cancer: when adoption of a novel treatment precedes prospective, randomized evidence. J Clin Oncol. https://doi.org/10.1200/JCO.19.01164
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A et al (2018) Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 36(11):1064–1072
Asher SA, White HN, Kejner AE, Rosenthal EL, Carroll WR, Magnuson JS (2013) Hemorrhage after transoral robotic-assisted surgery. Otolaryngol Head Neck Surg 149(1):112–117
Parhar HS, Gausden E, Patel J, Prisman E, Anderson DW, Durham JS et al (2018) Analysis of readmissions after transoral robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck 40(11):2416–2423
Dhanireddy B, Burnett NP, Sanampudi S, Wooten CE, Slezak J, Shelton B et al (2019) Outcomes in surgically resectable oropharynx cancer treated with transoral robotic surgery versus definitive chemoradiation. Am J Otolaryngol 40(5):673–677
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Fabian gibt an, dass kein Interessenkonflikt besteht. D. Krug erhielt Honorare von Merck Sharp & Dome.
Additional information
Originalpublikation
Nichols AC, Theurer J, Prisman E et al (2019) Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 20(10):1349-1359
Rights and permissions
About this article
Cite this article
Fabian, A., Krug, D. Radiotherapie versus transorale roboterassistierte Chirurgie in der Primärtherapie des Oropharynxkarzinoms: Randomisierung entscheidet. Strahlenther Onkol 196, 202–204 (2020). https://doi.org/10.1007/s00066-019-01567-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-019-01567-x